Jacqueline B. Naylor

Granta Park
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists.

Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists.

Journal: Pharmaceutics
Published: August 19, 2024

Stimulating intestinal GIP release reduces food intake and body weight in mice.

Stimulating intestinal GIP release reduces food intake and body weight in mice.

Journal: Molecular metabolism
Published: February 14, 2024

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake.

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake.

Journal: Frontiers in endocrinology
Published: May 04, 2023

Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease.

Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease.

Journal: Scientific reports
Published: July 28, 2021

Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries.

Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries.

Journal: Molecular metabolism
Published: July 22, 2021

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.

Journal: Nature metabolism
Published: June 02, 2020

Pharmacological antagonism of the incretin system protects against diet-induced obesity.

Pharmacological antagonism of the incretin system protects against diet-induced obesity.

Journal: Molecular metabolism
Published: November 10, 2019

Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition.

Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition.

Journal: The Journal of clinical investigation
Published: November 08, 2018

Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment.

Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment.

Journal: Scientific reports
Published: August 10, 2018

Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.

Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.

Journal: Diabetologia
Published: June 08, 2018

Development and characterisation of a novel glucagon like peptide-1 receptor antibody.

Development and characterisation of a novel glucagon like peptide-1 receptor antibody.

Journal: Diabetologia
Published: June 09, 2017

Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity.

Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity.

Journal: Current opinion in pharmacology
Published: June 05, 2017
Showing 1-12 of 21

Last Updated: 09/26/2026